Gonal-F and Male Fertility: Is it a Viable Option?
Gonal-F, also known as recombinant human follicle-stimulating hormone (r-hFSH), is primarily used to stimulate ovulation in women with infertility issues. However, it has been used off-label for men with fertility concerns, particularly those with low sperm counts or hypogonadotropic hypogonadism (HH).
Mechanism of Action
Gonal-F works by stimulating the testes to produce testosterone, which in turn promotes spermatogenesis, the process of sperm production [1]. In men with HH, the pituitary gland fails to produce sufficient gonadotropin-releasing hormone (GnRH), leading to decreased FSH and LH production. As a result, testosterone levels drop, and sperm production grinds to a halt. By administering Gonal-F, men with HH can bypass this deficiency and stimulate their testes to produce testosterone and increase sperm production.
Clinical Trials and Efficacy
Several studies have investigated the use of Gonal-F in men with fertility issues, particularly those with HH. A meta-analysis of 22 clinical trials found that Gonal-F significantly increased sperm count, motility, and morphology in men with HH [2]. Another study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that Gonal-F improved semen parameters in men with HH, leading to successful pregnancies [3].
Regulatory Status and Patient Safety
Gonal-F is a medication approved by the FDA for use in women with fertility issues. However, its use in men is considered off-label, meaning it is not specifically approved for this indication. The manufacturer, Merck, does not recommend using Gonal-F for male fertility, citing a lack of sufficient data on its safety and efficacy in men [4].
Who Makes Gonal-F?
Gonal-F is a product of Merck, a leading pharmaceutical company that also manufactures Keytruda (pembrolizumab), a cancer medication. Merck invests heavily in research and development, with a focus on creating innovative therapies for various diseases, including oncology and reproductive health [5].
Patent Expiration and Generic Availability
The patent for Gonal-F is set to expire in 2025, after which generic versions of the medication may become available. Generic competition could lead to increased accessibility and affordability of Gonal-F for both women and men, potentially extending its use beyond its approved indications [6].
What Happens If Gonal-F Fails to Work?
If Gonal-F fails to stimulate spermatogenesis, men with HH may require alternative fertility treatments, such as:
1. Testosterone replacement therapy
2. Intrauterine insemination (IUI) or in vitro fertilization (IVF) using donor sperm
3. Surgery to stimulate testicular function
Can Biosimilars Enter Before Patent Expiry?
The FDA allows biosimilars, or biologic drugs that mimic the effects of an existing medication, to enter the market before the patent expires. However, the agency only approves biosimilars that demonstrate equivalent safety, efficacy, and quality to the originator biologic [7].
References:
[1] http://www.drugpatentwatch.com/DrugPatent/Detail.aspx?id=1037 (Gonal-F)
[2] "Effectiveness of recombinant human follicle-stimulating hormone for idiopathic hypogonadotropic hypogonadism: a systematic review and meta-analysis," European Journal of Endocrinology.
[3] "Recombinant human follicle-stimulating hormone for the treatment of idiopathic hypogonadotropic hypogonadism," Journal of Clinical Endocrinology and Metabolism.
[4] https://www.merck.com/product/US/GONAL-F-ffs.html (Gonal-F)
[5] http://www.merck.com/about/our-story/
[6] http://www.drugpatentwatch.com/DrugPatent/Detail.aspx?id=1037 (Gonal-F)
[7] https://www.fda.gov/news-events/fda-brief/biosimilars-overview